My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Ifinatamab Biosimilar, B7-H3 Monoclonal Antibody

Ifinatamab Biosimilar, B7-H3 Monoclonal Antibody

B7 Homolog 3 Protein, CD276

Catalog No. Product Name Size List Price (US$) Quantity
C106P Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody 1 mg 175.00
C106P Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody 5 mg 600.00
C106P Ifinatamab Biosimilar, Human B7-H3 Monoclonal Antibody 20 mg 1200.00
C106P.NA Ifinatamab Biosimilar, N297A Mutant 0.5 mg 375.00
C106P.LA Ifinatamab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 0.5 mg 375.00
C106P.NA.05 Ifinatamab Biosimilar, N297A Mutant, Endotoxin 0.05 EU/mg 0.5 mg 575.00
Description

C106P: Ifinatamab Biosimilar, B7-H3 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human B7-H3 (CD276) monoclonal antibody ifinatamab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade ifinatamab biosimilar specifically binds to the human B7-H3 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ifinatamab .
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade ifinatamab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is ifinatamab biosimilar research grade? Ifinatamab is a humanized IgG1-kappa monoclonal antibody against  the human B7-H3 (CD276) protein, a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal (healthy) tissues. It was reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers. Ifinatamab biosimilar uses the same protein sequences as the therapeutic antibody ifinatamab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy